Therapeutic Solutions International (TSOI) 10-K 15 Apr 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	Apr. 16, 2018	Dec. 31, 2018	Jun. 30, 2018
Details
Registrant Name		THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Registrant CIK		0001419051
SEC Form		10-K
Period End date		Dec. 31, 2018
Fiscal Year End		--12-31
Trading Symbol		tsoi
Tax Identification Number (TIN)		451226465
Number of common stock shares outstanding	1,101,102,071
Public Float			$ 654,902
Filer Category		Non-accelerated Filer
Current with reporting		Yes
Voluntary filer		No
Well-known Seasoned Issuer		No
Shell Company		false
Small Business		true
Emerging Growth Company		false
Amendment Flag		false
Document Fiscal Year Focus		2018
Document Fiscal Period Focus		FY
Entity File Number		000-54554
Entity Incorporation, State Country Name		Nevada
Entity Address, Address Line One		4093 Oceanside Boulevard, Suite B
Entity Address, City or Town		Oceanside
Entity Address, State or Province		California
Entity Address, Postal Zip Code		92056
City Area Code		760
Local Phone Number		295-7208
Share Price			$ 0.0022
Entity Listing, Par Value Per Share	$ 0.001

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 22,397	$ 29
Inventory	0	1,515
Prepaid expenses and other current assets	113,521	1,054
Total current assets	135,918	2,598
Assets, Noncurrent	71,013	23,927
Total assets	206,931	26,525
Current liabilities:
Accounts payable	320,812	343,810
Accounts payable-related parties	7,981	0
Accrued expenses and other current liabilities	717,723	432,640
Convertible notes payable, net of discount of $105,556 and $28,541, at December 31, 2018 and 2017, respectively	45,784	27,459
Notes payable-related parties	458,487	429,201
Derivative Liability, Current	466,612	107,769
Total current liabilities	2,017,399	1,340,879
Shareholders' deficit:
Preferred shares	0	0
Common shares	1,011,063	806,501
Additional paid-in capital	4,314,047	3,147,811
Accumulated deficit	(7,135,578)	(5,268,666)
Total shareholders' deficit	(1,810,468)	(1,314,354)
Total liabilities and shareholders' deficit	$ 206,931	$ 26,525

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Details
Debt Instrument, Unamortized Discount, Current	$ 105,556	$ 28,541
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	2,500,000,000	990,000,000
Common Stock, Shares, Issued	1,011,063,182	806,501,000
Common Stock, Shares, Outstanding	1,011,063,182	806,501,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
Net Sales	$ 3,484	$ 2,851
Cost of Goods Sold	2,157	823
Gross Profit	1,327	2,028
Operating Expenses
General and administrative	405,871	107,380
Salaries, wages, and related costs	415,072	402,758
Selling expenses	2,493	3,310
Consulting fees	112,877	69,672
Legal and professional fees	189,853	278,069
Research and development	74,970	25,106
Total operating expenses	1,201,136	886,295
Operating Income (Loss)	(1,199,809)	(884,267)
Other income (expense):
Loss on derivative liability	(388,121)	(83,968)
Change in fair value of derivative liability	(37,230)	26,199
Interest expense	(241,752)	(53,436)
Total other income (expense)	(667,103)	(111,205)
Net Income (Loss)	$ (1,866,912)	$ (995,472)
Basic and diluted net loss per common share	$ 0	$ 0
Basic and diluted weighted-average common shares outstanding	896,851,647	778,150,315

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2016	$ 740,251	$ 2,878,111	$ (4,273,194)	$ (654,832)
Shares, Outstanding, Beginning Balance at Dec. 31, 2016	740,251,000
Stock Issued During Period, Value, Issued for Services	$ 18,500	126,450	0	144,950
Stock Issued During Period, Shares, Issued for Services	18,500,000
Stock Issued During Period, Value, New Issues	$ 47,750	143,250	0	191,000
Stock Issued During Period, Shares, New Issues	47,750,000
Net Income (Loss)	$ 0	0	(995,472)	(995,472)
Shares, Outstanding, Ending Balance at Dec. 31, 2017	806,501,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2017	$ 806,501	3,147,811	(5,268,666)	(1,314,354)
Stock Issued During Period, Value, Issued for Services	$ 77,500	545,750	0	623,250
Stock Issued During Period, Shares, Issued for Services	77,500,000
Stock Issued During Period, Value, New Issues	$ 61,000	188,000	0	249,000
Stock Issued During Period, Shares, New Issues	61,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 66,062	432,486	0	498,548
Stock Issued During Period, Shares, Conversion of Convertible Securities	66,062,182
Net Income (Loss)	$ 0	0	(1,866,912)	(1,866,912)
Shares, Outstanding, Ending Balance at Dec. 31, 2018	1,011,063,182
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2018	$ 1,011,063	$ 4,314,047	$ (7,135,578)	$ (1,810,468)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net Income (Loss)	$ (1,866,912)	$ (995,472)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation to consultants	303,750	144,950
Stock based compensation to related parties	319,500	0
Accrued interest, notes payable - related parties	10,380	28,414
Accounts payable, related parties	7,981	0
Loss on derivative liability	388,121	83,968
Change in fair value of derivative liabilities	37,230	(26,199)
Amortization of debt discount	194,985	27,459
Changes in operating assets and liabilities:
Inventory	1,515	34,920
Prepaid expenses and other current assets	(112,467)	13,250
Other assets	(47,086)	8,299
Accounts payable	(22,998)	16,218
Accrued expenses and other current liabilities	316,829	297,476
Net cash used in operating activities	(469,172)	(366,717)
Cash flows from financing activities:
Proceeds from issuance of common stock	249,000	191,000
Proceeds from convertible notes payable	245,000	50,000
Proceeds from notes payable - related parties	0	105,721
Payments on notes payable - related parties	(2,460)	(1,885)
Net cash provided by financing activities	491,540	344,836
Net increase (decrease) in cash	22,368	(21,881)
Cash and cash equivalents	10,202	32,083
Cash and cash equivalents	32,570	10,202
Supplemental disclosure of cash flow information
Cash paid for interest	4,608	3,565
Income Taxes Paid	1,600	0
Non-cash investing and financing transactions
Original issuance discount on convertible notes payable	27,000	6,000
Debt discount recorded in connection with derivative liability	245,000	50,000
Common stock issued in payment of convertible note payable	498,548	0
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	22,397	29
Restricted cash included in other assets	10,173	10,156
Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows	$ 32,570	$ 10,185

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2018
Notes
Note 1 - Nature of Business	Note 1 – Nature of business Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation. Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to cure certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. Nutraceutical Division ® ® Emvolio, Inc. , – was a wholly-owned subsidiary of TSI, incorporated in the State of Delaware on October 3, 2016, for the purpose of filing an Investigation New Drug (“IND”) application with the FDA for our StemVacs immunotherapy vaccine. In May of 2018 President Donald J. Trump signed into the law, the Right To Try bill. Because of this change, Emvolio has decided to withdraw the IND for a Phase 1 trial in the USA because TSI had previously completed a 10 patient trial in Mexico. TSI has since generated generated G ood C linical P ractice (“ GCP ”) documentation for the previously treated 10 patients into a Phase I trial, which will be presented to the FDA by TSI as part of an Ex-US trial compliant with 21 CFR 312.120 Foreign clinical studies not conducted under an IND. Therefore we have dissolved Emvolio, Inc. as it is no longer needed. SandBox Dental Labs, Inc. Management does not expect existing cash as of December 31, 2018 or as of March 31, 2019 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these December 31, 2018 financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2018, the Company has incurred losses totaling $7.1 million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes
Note 2 - Basis of Presentation and Significant Accounting Policies	Note 2 – Basis of presentation and significant accounting policies These consolidated financial statements have been prepared by management assuming that the Company will be able to continue as a going concern and realize its assets and discharge its liabilities in the normal course of business. However, certain conditions noted above currently exist which raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which our net assets are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. The accompanying financial statements do not reflect any adjustments related to the outcome of this uncertainty. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2018 and 2017, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $466,612 and $107,769 at December 31, 2018 and 2017, respectively. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2018, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the year ended December 31, 2018: Balance - December 31, 2017 $ 107,769 Issuance of new derivative liabilities 633,122 Conversions to paid-in capital (311,509) Change in fair market value of derivative liabilities 37,230 Balance – December 31, 2018 $ 466,612 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2018 and 2017, a total of 226,902,346 and zero , Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. During the years ended December 31, 2018 and 2017, there was no depreciation or amortization expense as all fixed assets have been fully depreciated. Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $74,970 and 25,106 for the years ended December 31, 2018 and 2017, respectiverly. Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company has elected to early adopt. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019 and will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 was effective for the Company in the first quarter of 2018 and allows for full retrospective or a modified retrospective adoption approach. The adoption of this standard did not have a material impact on the Company’s financial position or results of operations. The Financial Accounting Standards Board (FASB) issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company has elected to early adopt. Reclassifications Certain reclassifications have been made to the prior year’s consolidated financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of consolidated operations or equity.

Note 3 - Restricted Cash

Note 3 - Restricted Cash	12 Months Ended
	Dec. 31, 2018
Notes
Note 3 - Restricted Cash	Note 3 – Restricted cash Included in non-current asset is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2019, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Note 4 - Prepaid expense and ot

Note 4 - Prepaid expense and other current assets	12 Months Ended
	Dec. 31, 2018
Notes
Note 4 - Prepaid expense and other current assets	Note 4 – Prepaid expense and other current assets: Prepaid expenses and other current assets consist of the following: December 31, 2018 December 31, 2017 Prepaid Consulting $ 111,655 $ - Insurance 848 1,054 Prepaid costs 1,018 - Total $ 113,521 $ 1,054

Note 5 - Fixed assets

Note 5 - Fixed assets	12 Months Ended
	Dec. 31, 2018
Notes
Note 5 - Fixed assets	Note 5 – Fixed assets Fixed assets consist of the following: December 31, 2018 December 31, 2017 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ - Depreciation expense was $0 for December 31, 2018 and 2017.

Note 6 - Other Assets

Note 6 - Other Assets	12 Months Ended
	Dec. 31, 2018
Notes
Note 6 - Other Assets	Note 6 – Other Assets Other assets consist of the following: December 31, 2018 December 31, 2017 Prepaid Consulting $ 56,718 $ - Deposit 4,123 4,123 Restricted cash 10,172 10,156 Prepaid costs - 9,648 Total $ 71,013 $ 23,927

Note 7 - Convertible Notes Paya

Note 7 - Convertible Notes Payable	12 Months Ended
	Dec. 31, 2018
Notes
Note 7 - Convertible Notes Payable	Note 7 – Convertible notes payable On July 24, 2017 and September 7, 2017, the Company entered into two $28,000 convertible promissory notes with a third party for which the proceeds were used for operations. The Company received net proceeds of $50,000 and thus a $6,000 original issuance discount was recorded. The convertible promissory notes incur interest at 12% per annum for which $28,000 plus accrued interest were due on April 30, 2018 and June 15, 2018. The convertible promissory notes were convertible to shares of the Company's common stock 180 days after issuance. The conversion price per share was equal to 55% of the average of the three (3) lowest trading price of the Company's common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The Company had the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120 of 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes included various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. These notes were fully converted into 18,907,307 shares of common stock during the year ended December 31, 2018. On January 3, 2018, February 27, 2018, May 1, 2018, June 5, 2018, July 2, 2018, August 6, 2018, October 3, 2018, November 15, 2018, and December 6, 2018, the Company entered into five $28,000 convertible promissory notes and four $33,000 convertible promissory notes with a third party for which the proceeds were used for operations. The Company received net proceeds of $245,000 and a $27,000 original issuance discount was recorded. The convertible promissory notes incur interest at 12% per annum for which $28,000 plus accrued interest are/were due on October 15, 2018, November 20, 2018, February 15, 2019, April 15, 2019 and May 30, 2019 and $33,000 plus accrued interest are/were due March 30, 2019, July 30, 2019, August 30, 2019, and September 30, 2019. The convertible promissory notes are convertible to shares of the Company's common stock 180 days after issuance. The conversion price per share is equal to 55% of the average of the three (3) lowest trading prices of the Company's common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company was required to reserve at December 31, 2018, a total of 659,706,845 common shares in connection with the promissory notes. Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. On July 24, 2017 and September 7, 2017, the convertible note issuance dates, the Company valued the conversion feature resulting in initial liability of $133,968. Since the fair value of the derivatives were in excess of the proceeds received of $50,000, a full discount to convertible notes payable and a day one loss on derivative liabilities of $83,968 was recorded. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from of $0.003 to $0.004, the closing stock price of the Company's common stock on the date of valuation ranging from $0.008 to $0.009, an expected dividend yield of 0%, expected volatility ranging from 299% to 319%, risk-free interest rates ranging from 1.21% to 1.23%, and an expected term of 0.77 years. On December 31, 2017, the derivative liabilities were revalued at $107,769 resulting in a loss of $57,769 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion price of $0.003, the closing stock price of the Company's common stock on the date of valuation of $0.008, an expected dividend yield of 0%, expected volatility ranging from 330% to 341%, risk-free interest rate of 1.31%, and an expected term ranging from 0.33 to 0.45 years. For the nine notes issued during the year ended December 31, 2018, the Company valued the conversion feature on the date of issuance resulting in initial liability of $633,121. Since the fair value of the derivatives were in excess of the proceeds received of $245,000, a full discount to convertible notes payable and a day one loss on derivative liabilities of $388,121 was recorded during the year ended December 31, 2018. Upon issuance, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.002 to $0.006, the closing stock price of the Company's common stock on the date of valuation ranging from $0.0045 to $0.0220, an expected dividend yield of 0%, expected volatility ranging from 214% to 304%, risk-free interest rates ranging from 1.81% to 2.70%, and an expected term ranging from 0.76 to 0.82 years. During the year ended December 31, 2018, five of the $28,000 convertible notes and one of the $33,000 convertible notes were converted into 66,062,182 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended December 31, 2018, the Company recorded a gain of $165,563 related to the change of fair value of the derivative liability and recorded $311,509 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0033 to $0.005 the closing stock price of the Company's common stock on the date of valuation ranging from $0.0028 to $0.02720, an expected dividend yield of 0%, expected volatility ranging from 185% to 277%, risk-free interest rates ranging from 1.81% to 2.70%, and expected terms ranging from 0.07 to 0.75 years. On December 31, 2018, the derivative liabilities on the remaining five convertible notes were revalued at $466,612 resulting in a loss of $388,121for the year ended December 31, 2018 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.002, the closing stock price of the Company's common stock on the date of valuation of $0.0055, an expected dividend yield of 0%, expected volatility ranging from 248% to 279%, risk-free interest rate of 2.63%, and an expected term ranging from 0.29 to 0.75 years. The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2018 and 2017, the Company amortized $194,985 and $27,459 to interest expense, respectively. As of December 31, 2018, discounts of $105,556 remained for which will be amortized through September 30, 2019.

Note 8 - Notes Payable - Relate

Note 8 - Notes Payable - Related Parties	12 Months Ended
	Dec. 31, 2018
Notes
Note 8 - Notes Payable - Related Parties	Note 8 – Notes payable-related parties Notes payable-related parties consist of: 2018 2017 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019 $ 17,015 $ 15,868 Three notes payable – Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity dates of December 31, 2019. 138,105 132,366 Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019. 99,200 92,800 Two notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity dates of April 20, 2019 204,167 188,167 $ 458,487 $ 429,201

Note 9 - Related party transact

Note 9 - Related party transactions	12 Months Ended
	Dec. 31, 2018
Notes
Note 9 - Related party transactions	Note 9 – Related party transactions As of December 31, 2018 and 2017, the Company accrued officers’ salary of $663,100 and $391,000, respectively. On January 17, 2017 , we issued 12,500,000 shares of common stock , valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On March 2, 2017 , we issued 12,500,000 shares of common stock , valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On April 20, 2017, we issued a six month convertible note in the amount of $100,000 with an annual interest rate of 10% to a related party. On October 20, 2017, we issued 12,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On October 25, 2018, we issued 15,000,000 shares of common stock, valued at .0071 each to two officers and one director of the Company under a Restricted Stock Award. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company has elected to early adopt.

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes
Note 10 - Income Taxes	Note 10 – Income taxes The Company is subject to United States federal and state income taxes at an approximate rate of 30%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2018 December 31, 2017 Expected income tax at statutory rate $ (391,884) $ (338,188) State tax 168 272 Permanent differences 253,768 829 Change in valuation allowance 149,704 (223,742) Change in tax rate - 561,529 Other (11,756) 100 Provision for income taxes $ - $ 800 The significant components of deferred income tax assets and liabilities at December 31, 2018 and 2017 are as follows: December 31, 2018 December 31, 2017 Net operating loss carry-forward $ 1,321,683 $ 1,208,949 Valuation allowance (1,321,683) (1,208,949) Net deferred income tax asset $ - $ - The Company has net operating losses carried forward of approximately $5 million and $4.3 million as of December 31, 2018 and 2017, respectively, available to offset taxable income in future years which expire beginning in fiscal 2032. As of and for the years ended December 31, 2018 and 2017, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2018 and 2017. On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the “Act”) resulting in significant modifications to existing law including lowering the corporate tax rate from 34% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income we may have, the legislation affects the way we can use and carry forward net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on our balance sheet. The Company has completed the accounting for the effects of the Act during the year ended December 31, 2018. Given that current deferred tax assets are offset by a full valuation allowance, these changes did not have an impact on the balance sheet.

Note 11 - Equity

Note 11 - Equity	12 Months Ended
	Dec. 31, 2018
Notes
Note 11 - Equity	Note 11 – Equity Our authorized capital stock consists of an aggregate of 2,505,000,000 shares, comprised of 2,500,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of December 31, 2018, we have 1,011,063,182 shares of Common Stock and no preferred shares issued and outstanding. Issuances of Unregistered Securities On January 17, 2017 , we issued 12,500,000 shares of common stock , valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On March 2, 2017, we issued 12,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On April 3, 2017, we issued 1,000,000 shares of common stock, valued at $0.0067 per share for consulting services. On April 20, 2017, we issued a six month convertible note in the amount of $100,000 with an annual interest rate of 10% to a related party. On April 28, 2017 , we issued 10,000,000 shares of common stock , valued at $0.008 per share, for legal services and 1,000,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement. On July 6, 2017, we issued 2,000,000 shares of common stock, valued at $0.0083 per share for consulting services. On July 24, 2017, we issued a six month convertible note in the amount of $28,000 with an annual interest rate of 10%. On August 21, 2017, we issued 6,250,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement and 1,000,000 shares of common stock, valued at $0.0053 per share, for consulting services. On August 28, 2017, we issued 2,000,000 shares of common stock, valued at $0.0063 per share, for consulting services. On September 7, 2017, we issued a six month convertible note in the amount of $28,000 with an annual interest rate of 10%. On September 20, 2017, we issued 3,000,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On October 2, 2017, we issued 2,500,000 shares of common stock, valued at $0.0095 per share for consulting services. On October 20, 2017, we issued 12,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On January 26, 2018, we issued 2,424,242 shares of common stock for the partial conversion of $8,000 for convertible note dated July 24, 2017. On February 1, 2018, we issued 6,376,471 shares of common stock for the conversion of the balance of $20,000 for convertible note dated July 24, 2017. On February 1, 2018, we issued 5,000,000 shares of common stock, valued at $0.009 per share, for consulting services. On February 1, 2018, we issued 2,500,000 shares of common stock, valued at $0.009 per share, for consulting services. On February 20, 2018, we issued 15,000,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On February 20, 2018, we issued 2,500,000 shares of common stock, valued at $0.0062 per share, for consulting services. On April 14, 2018, we issued 2,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On April 14, 2018, we issued 5,000,000 shares of common stock, valued at $0.0057 per share, for consulting services. On April 27, 2018, we issued 3,225,806 shares of common stock for the partial conversion of $8,000 for convertible note dated September 7, 2017. On May 1, 2018, we issued 4,137,931 shares of common stock for the partial conversion of $12,000 for convertible note dated September 7, 2017. On May 2, 2018, we issued 25,000,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On May 21, 2018, we issued 2,742,857 shares of common stock for the partial conversion of $6,000 for convertible note dated September 7, 2017. On June 15, 2018, we issued 8,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement. On July 3, 2018, we issued 5,000,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement. On July 9, 2018, we issued 4,166,667 shares of common stock for the partial conversion of $15,000 for convertible note dated January 3, 2018. On July 12, 2018, we issued 4,077,778 shares of common stock for the partial conversion of $13,000 for convertible note dated January 3, 2018. On July 19, 2018, we issued 2,500,000 shares of common stock, valued at $0.015 per share, to a Scientific Advisory Board member for consulting services. On August 7, 2018, we issued 11,000,000 shares of common stock at $0.011 per share, for consulting services. On September 5, 2018, we issued 3,260,870 shares of common stock for the partial conversion of $15,000 for convertible note dated February 27, 2018. On September 10, 2018, we issued 3,262,222 shares of common stock for the partial conversion of $13,000 for convertible note dated February 27, 2018. On September 19, 2018, we issued 5,000,000 shares of common stock, valued at $0.005 per share, for an investment in the Company’s Private Placement. On September 19, 2018, we issued 1,500,000 shares of common stock, valued at $0.01 per share, to a Scientific Advisory Board member for consulting services. On October 25, 2018, we issued 15,000,000 shares of common stock, valued at .0071 each to two officers and one director of the Company under a Restricted Stock Award. On November 15, 2018, we issued 2,500,000 shares of common stock, valued at $0.008 per share, to a Scientific Advisory Board member for consulting services. On November 23, 2018, we issued 3,805,899 shares of common stock for the partial conversion of $12,000 for convertible note dated May 1, 2018. On November 26, 2018, we issued 4,347,826 shares of common stock for the partial conversion of $10,000 for convertible note dated May 1, 2018. On November 28, 2018, we issued 3,657,143 shares of common stock for the partial conversion of $6,000 for convertible note dated May 1, 2018. On December 7, 2018, we issued 8,823,529 shares of common stock for the partial conversion of $15,000 for convertible note dated June 5, 2018. On December 14, 2018, we issued 5,882,353 shares of common stock for the partial conversion of $10,000 for convertible note dated June 5, 2018. On December 17, 2018, we issued 5,870,588 shares of common stock for the partial conversion of $8,000 for convertible note dated June 5, 2018. On January 3, 2019, we issued 15,000,000 shares of common stock, valued at .0071 each to two officers and one director of the Company under a Restricted Stock Award. On January 3, 2019, we issued 10,000,000 shares of common stock, valued at $0.005 per share, to a Scientific Advisory Board member for consulting services. On January 7, 2019, we issued 7,500,000 shares of common stock for the partial conversion of $12,000 for convertible note dated July 2, 2018. On January 9, 2019, we issued 6,250,000 shares of common stock for the partial conversion of $10,000 for convertible note dated July 2, 2018. On January 9, 2019, we issued 4,800,000 shares of common stock for the partial conversion of $7.680 for convertible note dated July 2, 2018. On February 8, 2019, we issued 8,333,333 shares of common stock for the partial conversion of $10,000 for convertible note dated August 6, 2018. On February 12, 2019, we issued 8,155,556 shares of common stock for the partial conversion of $14,680 for convertible note dated August 6, 2018.

Note 12 - Legal proceedings

Note 12 - Legal proceedings	12 Months Ended
	Dec. 31, 2018
Notes
Note 12 - Legal proceedings	Note 12 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes
Note 13 - Commitments and Contingencies	Note 13 – Commitments and Contingencies Effective May 1, 2017, the Company entered into a fourth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 square feet and the amendment is for a term of 36 months and expires on April 30, 2020. During the year ended December 31, 2018 and 2017,the Company incurred rent expense of $21,774 and $21,145. Future minimum lease payments as of December 31, 2018 are as follows: 2019 $ 22,272 2020 $ 7,492

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes
Note 14 - Subsequent Events	Note 14 – Subsequent events On January 2, 2019, we issued a nine month convertible note in the amount of $33,000 with an annual interest rate of 12%. On January 3, 2019, we issued 15,000,000 shares of common stock, valued at .0071 each to two officers and one director of the Company under a Restricted Stock Award. On January 3, 2019, we issued 10,000,000 shares of common stock, valued at $0.005 per share, to a Scientific Advisory Board member for consulting services. On January 7, 2019, we issued 7,500,000 shares of common stock for the partial conversion of $12,000 for convertible note dated July 2, 2018. On January 9, 2019, we issued 6,250,000 shares of common stock for the partial conversion of $10,000 for convertible note dated July 2, 2018. On January 9, 2019, we issued 4,800,000 shares of common stock for the partial conversion of $7,680 for convertible note dated July 2, 2018. On February 2, 2019, we issued a nine month convertible note in the amount of $33,000 with an annual interest rate of 12%. On February 8, 2019, we issued 8,333,333 shares of common stock for the partial conversion of $10,000 for convertible note dated August 6, 2018. On February 12, 2019, we issued 8,155,556 shares of common stock for the partial conversion of $14,680 for convertible note dated August 6, 2018. On March 11, 2019, we issued a nine month convertible note in the amount of $28,000 with an annual interest rate of 12%. In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2018 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Significant Accounting Policies: Principles of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Note 2 - Basis of Presentatio_3

Note 2 - Basis of Presentation and Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation.

Note 2 - Basis of Presentatio_4

Note 2 - Basis of Presentation and Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

Note 2 - Basis of Presentatio_5

Note 2 - Basis of Presentation and Significant Accounting Policies: Derivative Liabilities (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2018 and 2017, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $466,612 and $107,769 at December 31, 2018 and 2017, respectively.

Note 2 - Basis of Presentatio_6

Note 2 - Basis of Presentation and Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2018, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the year ended December 31, 2018: Balance - December 31, 2017 $ 107,769 Issuance of new derivative liabilities 633,122 Conversions to paid-in capital (311,509) Change in fair market value of derivative liabilities 37,230 Balance – December 31, 2018 $ 466,612

Note 2 - Basis of Presentatio_7

Note 2 - Basis of Presentation and Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.

Note 2 - Basis of Presentatio_8

Note 2 - Basis of Presentation and Significant Accounting Policies: Comprehensive Loss (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.

Note 2 - Basis of Presentatio_9

Note 2 - Basis of Presentation and Significant Accounting Policies: Net Loss Per Share (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2018 and 2017, a total of 226,902,346 and zero ,

Note 2 - Basis of Presentati_10

Note 2 - Basis of Presentation and Significant Accounting Policies: Depreciation and Amortization (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Depreciation and Amortization	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. During the years ended December 31, 2018 and 2017, there was no depreciation or amortization expense as all fixed assets have been fully depreciated.

Note 2 - Basis of Presentati_11

Note 2 - Basis of Presentation and Significant Accounting Policies: Long-lived Assets (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

Note 2 - Basis of Presentati_12

Note 2 - Basis of Presentation and Significant Accounting Policies: Research and Development (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Research and Development	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $74,970 and 25,106 for the years ended December 31, 2018 and 2017, respectiverly.

Note 2 - Basis of Presentati_13

Note 2 - Basis of Presentation and Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”

Note 2 - Basis of Presentati_14

Note 2 - Basis of Presentation and Significant Accounting Policies: Stock-Based Compensation (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company has elected to early adopt.

Note 2 - Basis of Presentati_15

Note 2 - Basis of Presentation and Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019 and will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 was effective for the Company in the first quarter of 2018 and allows for full retrospective or a modified retrospective adoption approach. The adoption of this standard did not have a material impact on the Company’s financial position or results of operations. The Financial Accounting Standards Board (FASB) issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company has elected to early adopt.

Note 2 - Basis of Presentati_16

Note 2 - Basis of Presentation and Significant Accounting Policies: Reclassifications (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Reclassifications	Reclassifications Certain reclassifications have been made to the prior year’s consolidated financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of consolidated operations or equity.

Note 2 - Basis of Presentati_17

Note 2 - Basis of Presentation and Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of Change in Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Change in Derivative Liability	Balance - December 31, 2017 $ 107,769 Issuance of new derivative liabilities 633,122 Conversions to paid-in capital (311,509) Change in fair market value of derivative liabilities 37,230 Balance – December 31, 2018 $ 466,612

Note 4 - Prepaid expense and _2

Note 4 - Prepaid expense and other current assets: Schedule of Prepaid expenses and other current assets (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Prepaid expenses and other current assets	December 31, 2018 December 31, 2017 Prepaid Consulting $ 111,655 $ - Insurance 848 1,054 Prepaid costs 1,018 - Total $ 113,521 $ 1,054

Note 5 - Fixed assets_ Property

Note 5 - Fixed assets: Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Property, Plant and Equipment	December 31, 2018 December 31, 2017 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ -

Note 6 - Other Assets_ Schedule

Note 6 - Other Assets: Schedule of Other Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Other Assets	December 31, 2018 December 31, 2017 Prepaid Consulting $ 56,718 $ - Deposit 4,123 4,123 Restricted cash 10,172 10,156 Prepaid costs - 9,648 Total $ 71,013 $ 23,927

Note 8 - Notes Payable - Rela_2

Note 8 - Notes Payable - Related Parties: Notes payable, Related Parties (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Notes payable, Related Parties	2018 2017 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019 $ 17,015 $ 15,868 Three notes payable – Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity dates of December 31, 2019. 138,105 132,366 Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019. 99,200 92,800 Two notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity dates of April 20, 2019 204,167 188,167 $ 458,487 $ 429,201

Note 10 - Income Taxes_ Schedul

Note 10 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	December 31, 2018 December 31, 2017 Expected income tax at statutory rate $ (391,884) $ (338,188) State tax 168 272 Permanent differences 253,768 829 Change in valuation allowance 149,704 (223,742) Change in tax rate - 561,529 Other (11,756) 100 Provision for income taxes $ - $ 800

Note 10 - Income Taxes_ Sched_2

Note 10 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	December 31, 2018 December 31, 2017 Net operating loss carry-forward $ 1,321,683 $ 1,208,949 Valuation allowance (1,321,683) (1,208,949) Net deferred income tax asset $ - $ -

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies: Schedule of Future Minimum Lease Payments (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Future Minimum Lease Payments	2019 $ 22,272 2020 $ 7,492

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details)	12 Months Ended
	Dec. 31, 2018
Details
Entity Incorporation, Date of Incorporation	Aug. 6, 2007
Entity Information, Former Legal or Registered Name	Friendly Auto Dealers, Inc.
Entity Incorporation, State Country Name	Nevada

Note 2 - Basis of Presentati_18

Note 2 - Basis of Presentation and Significant Accounting Policies: Derivative Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Details
Derivative Liability, Current	$ 466,612	$ 107,769

Note 2 - Basis of Presentati_19

Note 2 - Basis of Presentation and Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of Change in Derivative Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
Balance - December 31, 2017	$ 107,769
Issuance of new derivative liabilities	633,122
Conversions to paid-in capital	(311,509)
Change in fair value of derivative liabilities	37,230	$ (26,199)
Balance - December 31, 2018	$ 466,612	$ 107,769

Note 2 - Basis of Presentati_20

Note 2 - Basis of Presentation and Significant Accounting Policies: Net Loss Per Share (Details) - shares	Dec. 31, 2018	Dec. 31, 2017
Details
Antidilutive Common Shares Excluded from EPS calculation	226,902,346	0

Note 2 - Basis of Presentati_21

Note 2 - Basis of Presentation and Significant Accounting Policies: Depreciation and Amortization (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
Depreciation	$ 0	$ 0
Amortization of Acquisition Costs	$ 0	$ 0

Note 3 - Restricted Cash (Detai

Note 3 - Restricted Cash (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
Details
Restricted Cash, Current	$ 10,000
Restricted Cash, Current, Nature of Restriction, Description	used as collateral for a Company credit card

Note 4 - Prepaid expense and _3

Note 4 - Prepaid expense and other current assets: Schedule of Prepaid expenses and other current assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Details
Prepaid Consulting	$ 111,655	$ 0
Insurance	848	1,054
Prepaid costs	1,018	0
Prepaid expenses and other current assets	$ 113,521	$ 1,054

Note 5 - Fixed assets_ Proper_2

Note 5 - Fixed assets: Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Computer Equipment
Property, Plant and Equipment, Gross	$ 10,747	$ 10,747
Office Equipment
Property, Plant and Equipment, Gross	3,639	3,639
Other Transportation Equipment
Property, Plant and Equipment, Gross	1,575	1,575
Property, Plant and Equipment, Gross	15,961	15,961
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(15,961)	(15,961)
Property, Plant and Equipment, Net	$ 0	$ 0

Note 6 - Other Assets_ Schedu_2

Note 6 - Other Assets: Schedule of Other Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Details
Prepaid Consulting	$ 56,718	$ 0
Deposit	4,123	4,123
Restricted cash	10,172	10,156
Prepaid costs	0	9,648
Assets, Noncurrent	$ 71,013	$ 23,927

Note 7 - Convertible Notes Pa_2

Note 7 - Convertible Notes Payable (Details)	12 Months Ended
	Dec. 31, 2018USD ($)$ / shares	Dec. 31, 2017USD ($)	Jun. 30, 2018$ / shares
Debt Instrument, Description	Company entered into two $28,000 convertible promissory notes with a third party for which the proceeds were used for operations
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Convertible, Terms of Conversion Feature	convertible to shares of the Company's common stock 180 days after issuance
Share Price			$ 0.0022
Amortization to Interest Expense | $	$ 194,985	$ 27,459
Discount Balance remaining to be amortized | $	$ 105,556
Conversion feature
Fair Value Assumptions, Expected Dividend Rate	0
Fair Value Assumptions, Expected Term	9 months 7 days
Conversion feature | Minimum
Fair Value Assumptions, Conversion Price	$ 0.003
Share Price	$ 0.008
Fair Value Assumptions, Expected Volatility Rate	2.9900
Fair Value Assumptions, Risk Free Interest Rate	0.0121
Conversion feature | Maximum
Fair Value Assumptions, Conversion Price	$ 0.004
Share Price	$ 0.009
Fair Value Assumptions, Expected Volatility Rate	3.1900
Fair Value Assumptions, Risk Free Interest Rate	0.0123
Revalued Derivative Liabilities
Fair Value Assumptions, Conversion Price	$ 0.003
Share Price	$ 0.008
Fair Value Assumptions, Expected Dividend Rate	0
Fair Value Assumptions, Risk Free Interest Rate	0.0131
Revalued Derivative Liabilities | Minimum
Fair Value Assumptions, Expected Volatility Rate	3.3000
Fair Value Assumptions, Expected Term	3 months 29 days
Revalued Derivative Liabilities | Maximum
Fair Value Assumptions, Expected Volatility Rate	3.4100
Fair Value Assumptions, Expected Term	5 months 12 days

Note 8 - Notes Payable - Rela_3

Note 8 - Notes Payable - Related Parties: Notes payable, Related Parties (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Note payable - Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2018
Long-term Debt	$ 17,015	$ 15,868
Three notes payable - Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity dates of December 31, 2018.
Long-term Debt	138,105	132,366
Note payable - Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2018,
Long-term Debt	99,200	92,800
Two notes payable - Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity dates of April 20, 2018
Long-term Debt	204,167	188,167
Long-term Debt	$ 458,487	$ 429,201

Note 9 - Related party transa_2

Note 9 - Related party transactions (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Debt Instrument, Interest Rate, Stated Percentage	12.00%		12.00%
Event 1
Stock Issued During Period, Shares, New Issues			15,000,000
Debt Instrument, Face Amount	$ 33,000		$ 33,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%		12.00%
Transaction 9
Sale of Stock, Description of Transaction	$663,100	$391,000
Transaction 10
Sale of Stock, Description of Transaction			we issued 12,500,000 shares of common stock
Sale of Stock, Transaction Date			Jan. 17, 2017
Stock Issued During Period, Shares, New Issues			12,500,000
Sale of Stock, Price Per Share	$ 0.004		$ 0.004
Transaction 11
Sale of Stock, Description of Transaction			we issued 12,500,000 shares of common stock
Sale of Stock, Transaction Date			Mar. 2, 2017
Stock Issued During Period, Shares, New Issues			12,500,000
Sale of Stock, Price Per Share	$ 0.004		$ 0.004
Transaction 12
Sale of Stock, Description of Transaction			we issued a six month convertible note
Sale of Stock, Transaction Date			Apr. 20, 2017
Debt Instrument, Face Amount	$ 100,000		$ 100,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%		10.00%
Transaction 13
Sale of Stock, Description of Transaction			we issued 12,500,000 shares of common stock
Sale of Stock, Transaction Date			Oct. 20, 2017
Stock Issued During Period, Shares, New Issues			12,500,000
Sale of Stock, Price Per Share	$ 0.004		$ 0.004

Note 10 - Income Taxes_ Sched_3

Note 10 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Details
Net operating loss carry-forward	$ 1,321,683	$ 1,208,949
Valuation allowance	(1,321,683)	(1,208,949)
Net deferred income tax asset	$ 0	$ 0

Note 11 - Equity (Details)

Note 11 - Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Common Stock, Shares Authorized	2,500,000,000	990,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Shares, Issued	1,011,063,182	806,501,000
Common Stock, Shares, Outstanding	1,011,063,182	806,501,000
Preferred Stock, Shares Issued	0
Preferred Stock, Shares Outstanding	0
Debt Instrument, Description	Company entered into two $28,000 convertible promissory notes with a third party for which the proceeds were used for operations
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Sale of Stock Transaction 1
Sale of Stock, Transaction Date	Jan. 17, 2017
Sale of Stock, Description of Transaction	we issued 12,500,000 shares of common stock
Shares, Issued	12,500,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 2
Sale of Stock, Transaction Date	Mar. 2, 2017
Sale of Stock, Description of Transaction	we issued 12,500,000 shares of common stock
Shares, Issued	12,500,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 3
Sale of Stock, Transaction Date	Apr. 3, 2017
Sale of Stock, Description of Transaction	we issued 1,000,000 shares of common stock
Shares, Issued	1,000,000
Sale of Stock, Price Per Share	$ 0.0067
Sale of Stock Transaction 4
Sale of Stock, Transaction Date	Apr. 20, 2017
Sale of Stock, Description of Transaction	we issued a six month convertible note
Debt Instrument, Description	six month convertible note
Debt Instrument, Face Amount	$ 100,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Sale of Stock Transaction 5
Sale of Stock, Transaction Date	Apr. 28, 2017
Sale of Stock, Description of Transaction	we issued 10,000,000 shares of common stock
Shares, Issued	10,000,000
Sale of Stock, Price Per Share	$ 0.008
Sale of Stock Transaction 6
Sale of Stock, Transaction Date	Apr. 28, 2017
Shares, Issued	1,000,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 7
Sale of Stock, Transaction Date	Jul. 6, 2017
Sale of Stock, Description of Transaction	we issued 2,000,000 shares of common stock
Shares, Issued	2,000,000
Sale of Stock, Price Per Share	$ 0.0083
Sale of Stock Transaction 8
Sale of Stock, Transaction Date	Jul. 24, 2017
Sale of Stock, Description of Transaction	we issued a six month convertible note
Debt Instrument, Description	ix month convertible note
Debt Instrument, Face Amount	$ 28,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Sale of Stock Transaction 9
Sale of Stock, Transaction Date	Aug. 21, 2017
Sale of Stock, Description of Transaction	we issued 6,250,000 shares of common stock
Shares, Issued	6,250,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 10
Sale of Stock, Transaction Date	Aug. 21, 2017
Shares, Issued	1,000,000
Sale of Stock, Price Per Share	$ 0.0053
Sale of Stock Transaction 11
Sale of Stock, Transaction Date	Aug. 28, 2017
Sale of Stock, Description of Transaction	we issued 2,000,000 shares of common stock
Shares, Issued	2,000,000
Sale of Stock, Price Per Share	$ 0.0063
Sale of Stock Transaction 12
Sale of Stock, Transaction Date	Sep. 7, 2017
Sale of Stock, Description of Transaction	we issued a six month convertible note
Debt Instrument, Description	six month convertible note
Debt Instrument, Face Amount	$ 28,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Sale of Stock Transaction 13
Sale of Stock, Transaction Date	Sep. 20, 2017
Sale of Stock, Description of Transaction	we issued 3,000,000 shares of common stock
Shares, Issued	3,000,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 14
Sale of Stock, Transaction Date	Oct. 2, 2017
Sale of Stock, Description of Transaction	we issued 2,500,000 shares of common stock
Shares, Issued	2,500,000
Sale of Stock, Price Per Share	$ 0.0095
Sale of Stock Transaction 15
Sale of Stock, Transaction Date	Oct. 20, 2017
Sale of Stock, Description of Transaction	we issued 12,500,000 shares of common stock
Shares, Issued	12,500,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 16
Sale of Stock, Transaction Date	Jan. 26, 2018
Sale of Stock, Description of Transaction	we issued 2,424,242 shares of common stock
Shares, Issued	2,424,242
Stock Issued	$ 8,000
Sale of Stock Transaction 17
Sale of Stock, Transaction Date	Feb. 1, 2018
Sale of Stock, Description of Transaction	we issued 6,376,471 shares of common stock
Shares, Issued	6,376,471
Stock Issued	$ 20,000
Sale of Stock Transaction 18
Sale of Stock, Transaction Date	Feb. 1, 2018
Sale of Stock, Description of Transaction	we issued 5,000,000 shares of common stock
Shares, Issued	5,000,000
Sale of Stock, Price Per Share	$ 0.009
Sale of Stock Transaction 19
Sale of Stock, Transaction Date	Feb. 1, 2018
Sale of Stock, Description of Transaction	we issued 2,500,000 shares of common stock
Shares, Issued	2,500,000
Sale of Stock, Price Per Share	$ 0.009
Sale of Stock Transaction 20
Sale of Stock, Transaction Date	Feb. 20, 2018
Sale of Stock, Description of Transaction	we issued 15,000,000 shares of common stock
Shares, Issued	15,000,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 21
Sale of Stock, Transaction Date	Feb. 20, 2018
Sale of Stock, Description of Transaction	we issued 2,500,000 shares of common stock
Shares, Issued	2,500,000
Sale of Stock, Price Per Share	$ 0.0062
Sale of Stock Transaction 22
Sale of Stock, Transaction Date	Apr. 14, 2018
Sale of Stock, Description of Transaction	we issued 2,500,000 shares of common stock
Shares, Issued	2,500,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 23
Sale of Stock, Transaction Date	Apr. 14, 2018
Sale of Stock, Description of Transaction	we issued 5,000,000 shares of common stock
Shares, Issued	5,000,000
Sale of Stock, Price Per Share	$ 0.0057
Sale of Stock Transaction 24
Sale of Stock, Transaction Date	Apr. 27, 2018
Sale of Stock, Description of Transaction	we issued 3,225,806 shares of common stock
Shares, Issued	3,225,806
Stock Issued	$ 8,000
Sale of Stock Transaction 25
Sale of Stock, Transaction Date	May 1, 2018
Sale of Stock, Description of Transaction	we issued 4,137,931 shares of common stock
Shares, Issued	4,137,931
Stock Issued	$ 12,000
Sale of Stock Transaction 26
Sale of Stock, Transaction Date	May 2, 2018
Sale of Stock, Description of Transaction	we issued 25,000,000 shares of common stock
Shares, Issued	25,000,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 27
Sale of Stock, Transaction Date	May 21, 2018
Sale of Stock, Description of Transaction	we issued 2,742,857 shares of common stock
Shares, Issued	2,742,857
Stock Issued	$ 6,000
Sale of Stock Transaction 28
Sale of Stock, Transaction Date	Jun. 15, 2018
Sale of Stock, Description of Transaction	we issued 8,500,000 shares of common stock
Shares, Issued	8,500,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 29
Sale of Stock, Transaction Date	Jul. 3, 2018
Sale of Stock, Description of Transaction	we issued 5,000,000 shares of common stock
Shares, Issued	5,000,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 30
Sale of Stock, Transaction Date	Jul. 9, 2018
Sale of Stock, Description of Transaction	we issued 4,166,667 shares of common stock
Shares, Issued	4,166,667
Stock Issued	$ 15,000
Sale of Stock Transaction 31
Sale of Stock, Transaction Date	Jul. 12, 2018
Sale of Stock, Description of Transaction	we issued 4,077,778 shares of common stock
Shares, Issued	4,077,778
Stock Issued	$ 13,000
Sale of Stock Transaction 32
Sale of Stock, Transaction Date	Jul. 19, 2018
Sale of Stock, Description of Transaction	we issued 2,500,000 shares of common stock
Shares, Issued	2,500,000
Sale of Stock, Price Per Share	$ 0.015
Sale of Stock Transaction 33
Sale of Stock, Transaction Date	Aug. 7, 2018
Sale of Stock, Description of Transaction	we issued 11,000,000 shares of common stock
Shares, Issued	11,000,000
Sale of Stock, Price Per Share	$ 0.011
Sale of Stock Transaction 34
Sale of Stock, Transaction Date	Sep. 5, 2018
Sale of Stock, Description of Transaction	we issued 3,260,870 shares of common stock
Shares, Issued	3,260,870
Stock Issued	$ 15,000
Sale of Stock Transaction 35
Sale of Stock, Transaction Date	Sep. 10, 2018
Sale of Stock, Description of Transaction	we issued 3,262,222 shares of common stock
Shares, Issued	3,262,222
Stock Issued	$ 13,000
Sale of Stock Transaction 36
Sale of Stock, Transaction Date	Sep. 19, 2018
Sale of Stock, Description of Transaction	we issued 5,000,000 shares of common stock,
Shares, Issued	5,000,000
Sale of Stock, Price Per Share	$ 0.005
Sale of Stock Transaction 37
Sale of Stock, Transaction Date	Sep. 19, 2018
Sale of Stock, Description of Transaction	we issued 1,500,000 shares of common stock
Shares, Issued	1,500,000
Sale of Stock, Price Per Share	$ 0.01
Sale of Stock Transaction 38
Sale of Stock, Transaction Date	Oct. 25, 2018
Sale of Stock, Description of Transaction	we issued 15,000,000 shares of common stock
Shares, Issued	15,000,000
Sale of Stock, Price Per Share	$ 71
Sale of Stock Transaction 39
Sale of Stock, Transaction Date	Nov. 15, 2018
Sale of Stock, Description of Transaction	we issued 2,500,000 shares of common stock
Shares, Issued	2,500,000
Sale of Stock, Price Per Share	$ 0.008
Sale of Stock Transaction 40
Sale of Stock, Transaction Date	Nov. 23, 2018
Sale of Stock, Description of Transaction	we issued 3,805,899 shares of common stock
Shares, Issued	3,805,899
Stock Issued	$ 12,000
Sale of Stock Transaction 41
Sale of Stock, Transaction Date	Nov. 26, 2018
Sale of Stock, Description of Transaction	we issued 4,347,826 shares of common stock
Shares, Issued	4,347,826
Stock Issued	$ 10,000
Sale of Stock Transaction 42
Sale of Stock, Transaction Date	Nov. 28, 2018
Sale of Stock, Description of Transaction	we issued 3,657,143 shares of common stock
Shares, Issued	3,657,143
Stock Issued	$ 6,000
Sale of Stock Transaction 43
Sale of Stock, Transaction Date	Dec. 7, 2018
Sale of Stock, Description of Transaction	we issued 8,823,529 shares of common stock
Shares, Issued	8,823,529
Stock Issued	$ 15,000
Sale of Stock Transaction 44
Sale of Stock, Transaction Date	Dec. 14, 2018
Sale of Stock, Description of Transaction	we issued 5,882,353 shares of common stock
Shares, Issued	5,882,353
Stock Issued	$ 10,000
Sale of Stock Transaction 45
Sale of Stock, Transaction Date	Dec. 17, 2018
Sale of Stock, Description of Transaction	we issued 5,870,588 shares of common stock
Shares, Issued	5,870,588
Stock Issued	$ 8,000
Sale of Stock Transaction 46
Sale of Stock, Transaction Date	Jan. 3, 2019
Sale of Stock, Description of Transaction	we issued 15,000,000 shares of common stock
Shares, Issued	15,000,000
Sale of Stock, Price Per Share	$ 71
Sale of Stock Transaction 47
Sale of Stock, Transaction Date	Jan. 3, 2019
Sale of Stock, Description of Transaction	we issued 10,000,000 shares of common stock
Shares, Issued	10,000,000
Sale of Stock, Price Per Share	$ 0.005
Sale of Stock Transaction 49
Sale of Stock, Transaction Date	Jan. 7, 2019
Sale of Stock, Description of Transaction	we issued 7,500,000 shares of common stock
Shares, Issued	7,500,000
Stock Issued	$ 12,000
Sale of Stock Transaction 50
Sale of Stock, Transaction Date	Jan. 9, 2019
Sale of Stock, Description of Transaction	we issued 6,250,000 shares of common stock
Shares, Issued	6,250,000
Stock Issued	$ 10,000
Sale of Stock Transaction 51
Sale of Stock, Transaction Date	Jan. 9, 2019
Sale of Stock, Description of Transaction	we issued 4,800,000 shares of common stock
Shares, Issued	4,800,000
Stock Issued	$ 7.680
Sale of Stock Transaction 52
Sale of Stock, Transaction Date	Feb. 8, 2019
Sale of Stock, Description of Transaction	we issued 8,333,333 shares of common stock
Shares, Issued	8,333,333
Stock Issued	$ 10,000
Sale of Stock Transaction 53
Sale of Stock, Transaction Date	Feb. 12, 2019
Sale of Stock, Description of Transaction	we issued 8,155,556 shares of common stock
Shares, Issued	8,155,556
Stock Issued	$ 14,680

Note 13 - Commitments and Con_3

Note 13 - Commitments and Contingencies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
Payments for Rent	$ 21,774	$ 21,145

Note 13 - Commitments and Con_4

Note 13 - Commitments and Contingencies: Schedule of Future Minimum Lease Payments (Details)	Dec. 31, 2018USD ($)
Details
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 22,272
Operating Leases, Future Minimum Payments, Due in Two Years	$ 7,492

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details)	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Debt Instrument, Description	Company entered into two $28,000 convertible promissory notes with a third party for which the proceeds were used for operations
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Event 1
Subsequent Event, Date	Jan. 2, 2019
Subsequent Event, Description	we issued a nine month convertible note
Debt Instrument, Description	nine month convertible note
Debt Instrument, Face Amount	$ 33,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Event 2
Subsequent Event, Date	Jan. 3, 2019
Subsequent Event, Description	we issued 15,000,000 shares of common stock
Shares, Issued | shares	15,000,000
Sale of Stock, Price Per Share | $ / shares	$ 71
Event 3
Subsequent Event, Date	Jan. 3, 2019
Subsequent Event, Description	we issued 10,000,000 shares of common stock
Shares, Issued | shares	10,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.005
Event 4
Subsequent Event, Date	Jan. 7, 2019
Subsequent Event, Description	we issued 7,500,000 shares of common stock
Shares, Issued | shares	7,500,000
Stock Issued	$ 12,000
Event 5
Subsequent Event, Date	Jan. 9, 2019
Subsequent Event, Description	we issued 6,250,000 shares of common stock
Shares, Issued | shares	6,250,000
Stock Issued	$ 10,000
Event 6
Subsequent Event, Date	Jan. 9, 2019
Subsequent Event, Description	we issued 4,800,000 shares of common stock
Shares, Issued | shares	4,800,000
Stock Issued	$ 7,680
Event 7
Subsequent Event, Date	Feb. 2, 2019
Subsequent Event, Description	we issued a nine month convertible note
Debt Instrument, Description	nine month convertible note
Debt Instrument, Face Amount	$ 33,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Event 8
Subsequent Event, Date	Feb. 8, 2019
Subsequent Event, Description	we issued 8,333,333 shares of common stock
Shares, Issued | shares	8,333,333
Stock Issued	$ 10,000
Event 9
Subsequent Event, Date	Feb. 12, 2019
Subsequent Event, Description	we issued 8,155,556 shares of common stock
Shares, Issued | shares	8,155,556
Stock Issued	$ 14,680
Event 10
Subsequent Event, Date	Mar. 11, 2019
Subsequent Event, Description	we issued a nine month convertible note
Debt Instrument, Description	nine month convertible note
Debt Instrument, Face Amount	$ 28,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%